Jackson Grant Investment Advisers Inc. Has $63,000 Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Jackson Grant Investment Advisers Inc. trimmed its stake in shares of Zoetis Inc. (NYSE:ZTS) by 26.4% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 385 shares of the company’s stock after selling 138 shares during the quarter. Jackson Grant Investment Advisers Inc.’s holdings in Zoetis were worth $63,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Pensionfund Sabic grew its stake in Zoetis by 55.6% during the fourth quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock worth $1,825,000 after buying an additional 4,000 shares in the last quarter. PFW Advisors LLC bought a new stake in shares of Zoetis during the 4th quarter worth approximately $1,764,000. JPMorgan Chase & Co. boosted its position in shares of Zoetis by 10.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company’s stock worth $569,834,000 after acquiring an additional 279,092 shares in the last quarter. Simplify Asset Management Inc. bought a new position in Zoetis in the third quarter valued at approximately $11,684,000. Finally, Nordea Investment Management AB raised its position in Zoetis by 38.3% during the fourth quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company’s stock valued at $336,266,000 after purchasing an additional 572,511 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Up 2.0 %

Zoetis stock opened at $175.65 on Thursday. The firm has a market cap of $79.25 billion, a price-to-earnings ratio of 33.02, a PEG ratio of 2.72 and a beta of 0.90. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.53. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The firm has a 50 day moving average price of $169.41 and a two-hundred day moving average price of $179.35.

Zoetis (NYSE:ZTS) last announced its earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. The business had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. Zoetis’s quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter last year, the firm earned $1.36 earnings per share. Equities analysts predict that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be given a $0.50 dividend. The ex-dividend date of this dividend is Tuesday, January 21st. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 annualized dividend and a dividend yield of 1.14%. Zoetis’s dividend payout ratio (DPR) is 37.59%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ZTS. Stifel Nicolaus reduced their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Morgan Stanley reduced their price objective on Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. UBS Group assumed coverage on Zoetis in a research report on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price on the stock. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Finally, Leerink Partners initiated coverage on shares of Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $215.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.